NewsResearch
FDA Approval: Crizotinib (Xalkori) for Lung cancer
FDA approved Crizotinib (Xalkori), an ALK inhibitor, for certain people with lung cancer. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Historical context: this page explains an event dated 2011. It was published as an explainer on July 12, 2026 and is not breaking news.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
In brief
FDA approved Crizotinib (Xalkori) — ALK inhibitor — for certain people with lung cancer. This page explains what that means in plain language and where the limits are.
Approval at a glance
| Field | Detail |
|---|---|
| Drug | Crizotinib (Xalkori) |
| Regulator | FDA |
| Date | 2011 |
| Cancer type | Lung cancer |
| Treatment class | ALK inhibitor |
| Eligible population | Certain people with lung cancer |
| Approval type | first approval |
What was approved
Crizotinib (Xalkori) (ALK inhibitor) received a first approval from the FDA for use in certain people with lung cancer, reported for 2011. Eligibility is defined by the official label; whether it fits a specific person is a clinical decision.
The evidence behind it
The approval was based on the clinical evidence summarized in the FDA's announcement and the product label.
What this does and doesn't change
Approvals like this can expand options for certain people with lung cancer, but they do not change care for everyone, and access, cost, and side effects still matter.
What this does not mean
- An approval defines who is eligible in general terms; whether it fits a specific person is an individual clinical decision.
- Approval is not a promise of cure or of benefit for every patient — it means the evidence met the regulator's bar for this use.
- Labels and evidence can change over time as more data arrive.
Questions you might bring to a clinician
- Am I in the group this treatment was approved for?
- How does it compare with my current options?
- What are the costs, logistics, and side effects?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
- AACR/PMC FDA Approval Summary: Crizotinib for ALK-rearranged metastatic NSCLC (secondary)
- Xalkori (crizotinib) FDA approval history (first approval 2011) (secondary)
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.